

Route Mobile posted a weak operating performance in Q1, although adjusted for one-offs, performance was broadly inline. Revenue grew 8.5% QoQ, in line with our estimate, aided by the Vi deal and incremental throughput from Telesign. Billable transactions jumped up 9.1% QoQ on the back of volume growth in the domestic market, whereas average realization was broadly stable QoQ at ~30paise. Reported EBITDAM fell by 110bps QoQ to 11.2%, missing expectations, although adj. EBITDAM was broadly in-line with expectations. Given the Q1 performance, ramp-up of the Vi firewall and expected synergy benefits (based on current run-rate on RPT transactions), the management expects revenue to grow 18-22% YoY in FY25, along with 13% non-GAAP EBITDAM and 50-75% cash generation (OCF/EBITDA). The management continues to aspire for US\$1bn revenue in the next 2-3 years. We cut FY25E EPS by ~4%, factoring in the Q1 performance and FY25 guidance, and largely retain FY26E/27E EPS. We retain ADD with a TP of Rs1,800 at 22x Jun-26E EPS.

Route Mobile: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	35,692	40,233	48,472	55,248	62,443
EBITDA	4,442	5,019	5,880	7,016	8,055
Adj. PAT	3,271	3,582	3,794	4,817	5,796
Adj. EPS (Rs)	52.4	59.7	60.4	76.7	92.3
EBITDA margin (%)	12.4	12.5	12.1	12.7	12.9
EBITDA growth (%)	103.1	13.0	17.1	19.3	14.8
Adj. EPS growth (%)	100.4	14.1	1.2	26.9	20.3
RoE (%)	18.7	18.0	16.5	18.1	18.8
RoIC (%)	34.9	24.4	22.0	25.2	27.7
P/E (x)	33.5	30.8	29.1	22.9	19.0
EV/EBITDA (x)	23.0	21.2	17.7	14.4	12.1
P/B (x)	6.0	5.1	4.5	3.9	3.3
FCFF yield (%)	0.3	(1.2)	2.6	3.7	4.6

Source: Company, Emkay Research

Results summary

Revenue grew 8.5% QoQ to Rs11.03bn, in line with our estimate of Rs11.06bn. the number of billable transactions grew to 37.1bn in Q1 from 34bn in Q4, and realizations were broadly stable QoQ at ~30paise. New product revenue grew 15.9% QoQ to Rs745mn in Q1FY25. Gross margin declined by 10bps to 21.7%. EBITDAM declined by 110bps QoQ to 11.2%, missing our estimate mainly due to one-offs like forex loss (Rs119mn) and one-time cost incurred for seeking expert opinions on transfer pricing for related-party transactions with Proximus and for the mandatory tender offer (Rs8.6mn). Adj. EBITDAM was broadly in line with expectations. Reported profit was Rs785mn, missing our expectations due to higher ETR and margin miss. Net revenue retention stood at 105% for Q1, with recurring revenue at 91%. The company added 2 new clients in the +USD15mn bucket, taking the total clients in the category to 7. **What we liked:** New products performance, growth in billable transactions. **What we did not like:** Margin miss, weak cash conversion on reported basis.


Earnings call KTAs

i) The management expects synergy benefits from the Proximus deal to start playing out gradually. FY25 guidance builds in the current RPT run-rate, and any improvement may drive an upside. Cost of sales benefit will have an immediate impact, while cross-charging on shared services would be seen from Q3. Cross-selling of new products is likely to take some time. ii) The recently-announced 5-year deal with Microsoft is an example of synergy benefits, and the management indicated it is pursuing a few more such deals. iii) The management highlighted YoY growth in ILD volumes supported by the Vi deal, although certain brands have lowered their volumes due to high pricing and are exploring alternate channels. The management seems convinced about achieving some growth in ILD volumes on the back of firewall installation at BSNL and Vi. iv) Employee cost sharply increased 27% QoQ on account of increments, one-off incentives given to retain talent, and reward for exhaustive integration work. This quarter on, it started expensed-out investments in digital identity project *Trusense*, amounting to Rs14.5mn (earlier, it used to capitalize this). It expects monthly employee costs of Rs200-210mn to be sustainable. v) Gross profit was impacted by non-cash impact of Rs38.8mn related to amortization of refundable security deposit provided to MNO. vi) The management plans to augment its product portfolio with acquisitions in a few cutting-edge futuristic technologies. The company plans maintaining the dividend payout ratio at up to 20% of PAT.

Target Price – 12M	Jun-25
Change in TP (%)	-
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	2.4
CMP (22-Jul-24) (Rs)	1,757.0

Stock Data	Ticker
52-week High (Rs)	1,942
52-week Low (Rs)	1,386
Shares outstanding (mn)	62.8
Market-cap (Rs bn)	110
Market-cap (USD mn)	1,319
Net-debt, FY25E (Rs mn)	-6,508
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	604.3
ADTV-3M (USD mn)	7.2
Free float (%)	42.0
Nifty-50	24,509
INR/USD	83.7
Shareholding, Jun-24	
Promoters (%)	83.1
FPIs/MFs (%)	5.8/1.0

Price Performance				
(%)	1M	3M	12M	
Absolute	14.9	15.1	17.9	
Rel. to Nifty	10.1	4.9	(5.0)	



Dipesh Mehta
 dipeshkumar.mehta@emkayglobal.com
 +91 22 6612 1253

Ayush Bansal
 ayush.bansal@emkayglobal.com
 +91 22 6612 1344

Pulkit Chawla
 pulkit.chawla@emkayglobal.com
 +91 22 6642 4258

Exhibit 1: Quarterly snapshot

(Rs mn)	Q1FY25	Q4FY24	QoQ (%)	Q1FY24	YoY (%)
Net sales	11,034	10,170	8.5	9,673	14.1
Operating expenses	9,797	8,916		8,442	
EBITDA	1,238	1,254	-1.3	1,232	0.5
Margin (%)	11.2	12.3	-110.0	12.7	(150.0)
Depreciation	223	219		211	
EBIT	1,015	1,036	-2.1	1,020	-0.6
Margin (%)	9.2	10.2	-100	10.5	(140.0)
Other income	14	40		82	
Pre-tax profit	1,029	1,076	-4.4	1,102	
Tax provided	217	142		185	
Profit after tax	812	952		917	
Emkay Net profit	785	881	-10.9	924	-15.1
EPS (Rs)	12.5	14.0	-10.9	14.8	-15.5

Source: Company, Emkay Research

Exhibit 2: Actuals vs estimates

(Rs mn)	Actual	Estimate		Variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Sales (Rs mn)	11,034	11,060	11,087	-0.2%	-0.5%	Revenues came broadly in line with our expectations
EBIT	1,015	1,150	1,131	-11.7%	-10.3%	Margins missed expectations due to forex loss and certain one-offs
EBIT margin	9.2%	10.4%	10.2%	-120 bps	-100 bps	
PAT	785	888	897	-11.6%	-12.5%	Reported profit was lower than expectations, due to operating performance miss


Source: Company, Emkay Research

Exhibit 3: Changes in estimates

(Rs mn)	FY25E			FY26E			FY27E		
	Old	New	Change	Old	New	Change	Old	New	Change
Revenue	48,480	48,472	0.0%	55,275	55,248	0.0%	62,414	62,443	0.0%
YoY growth (%)	20.5	20.5		14.0	14.0		12.9	13.0	
EBIT	5,106	4,974	-2.6%	6,092	6,089	-0.1%	7,115	7,119	0.1%
EBIT margins (%)	10.5	10.3		11.0	11.0		11.4	11.4	
Net profit	3,969	3,794	-4.4%	4,815	4,817	0.0%	5,789	5,796	0.1%
EPS (Rs)	63.2	60.4	-4.4%	76.7	76.7	0.0%	92.2	92.3	0.1%

Source: Company, Emkay Research

Exhibit 4: Route Mobile – One-year forward PER



Source: Company, Emkay Research

Route Mobile: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	35,692	40,233	48,472	55,248	62,443
Revenue growth (%)	78.3	12.7	20.5	14.0	13.0
EBITDA	4,442	5,019	5,880	7,016	8,055
EBITDA growth (%)	103.1	13.0	17.1	19.3	14.8
Depreciation & Amortization	816	861	906	928	936
EBIT	3,626	4,159	4,974	6,089	7,119
EBIT growth (%)	101.1	14.7	19.6	22.4	16.9
Other operating income	0	0	0	0	0
Other income	394	496	303	479	629
Financial expense	205	273	422	387	326
PBT	3,815	4,382	4,855	6,181	7,421
Extraordinary items	0	168	0	0	0
Taxes	484	662	944	1,236	1,484
Minority interest	(61)	(138)	(116)	(128)	(141)
Income from JV/Associates	0	0	0	0	0
Reported PAT	3,271	3,751	3,794	4,817	5,796
PAT growth (%)	96.8	14.7	1.2	26.9	20.3
Adjusted PAT	3,271	3,582	3,794	4,817	5,796
Diluted EPS (Rs)	52.4	59.7	60.4	76.7	92.3
Diluted EPS growth (%)	100.4	14.1	1.2	26.9	20.3
DPS (Rs)	5.0	11.0	11.0	14.0	17.0
Dividend payout (%)	9.5	18.4	18.2	18.3	18.4
EBITDA margin (%)	12.4	12.5	12.1	12.7	12.9
EBIT margin (%)	10.2	10.3	10.3	11.0	11.4
Effective tax rate (%)	12.7	15.1	19.4	20.0	20.0
NOPLAT (pre-IndAS)	3,166	3,530	4,007	4,871	5,695
Shares outstanding (mn)	62.4	62.8	62.8	62.8	62.8

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	3,815	4,382	4,855	6,181	7,421
Others (non-cash items)	1,019	713	906	928	936
Taxes paid	(334)	(746)	(944)	(1,236)	(1,484)
Change in NWC	(3,768)	(5,494)	(1,682)	(1,518)	(1,609)
Operating cash flow	732	(976)	3,135	4,354	5,265
Capital expenditure	(380)	(356)	(240)	(240)	(240)
Acquisition of business	(810)	(1,591)	374	(700)	0
Interest & dividend income	284	222	0	0	0
Investing cash flow	1,122	(21)	(3,722)	(2,940)	(3,240)
Equity raised/(repaid)	(1,492)	0	0	0	0
Debt raised/(repaid)	1,258	2,527	(46)	(600)	(500)
Payment of lease liabilities	(102)	(109)	0	0	0
Interest paid	(56)	(142)	0	0	0
Dividend paid (incl tax)	(686)	(696)	(691)	(879)	(1,067)
Others	(13)	3	0	0	0
Financing cash flow	(1,092)	1,584	(737)	(1,479)	(1,567)
Net chg in Cash	763	586	(1,324)	(65)	457
OCF	732	(976)	3,135	4,354	5,265
Adj. OCF (w/o NWC chg.)	4,500	4,518	4,816	5,872	6,873
FCFF	352	(1,332)	2,895	4,114	5,025
FCFE	431	(1,382)	2,472	3,728	4,698
OCF/EBITDA (%)	16.5	(19.4)	53.3	62.1	65.4
FCFE/PAT (%)	13.2	(36.8)	65.2	77.4	81.1
FCFF/NOPLAT (%)	11.1	(37.7)	72.2	84.5	88.2

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	624	628	628	628	628
Reserves & Surplus	17,580	20,868	23,972	27,909	32,638
Net worth	18,204	21,496	24,600	28,537	33,266
Minority interests	80	213	329	457	598
Deferred tax liability (net)	481	390	390	390	390
Total debt	1,401	3,785	3,739	3,139	2,639
Total liabilities & equity	20,166	25,883	29,057	32,522	36,892
Net tangible fixed assets	344	361	419	457	475
Net intangible assets	3,655	3,220	2,549	1,886	1,246
Net ROU assets	324	260	208	145	71
Capital WIP	151	267	267	267	267
Goodwill	5,202	5,125	5,125	5,125	5,125
Investments [JV/Associates]	0	0	0	0	0
Cash & equivalents	9,001	7,715	10,247	12,182	15,640
Current assets (ex-cash)	10,092	17,669	19,658	22,349	25,208
Current Liab. & Prov.	8,603	8,733	9,415	9,889	11,139
NWC (ex-cash)	1,489	8,935	10,242	12,460	14,069
Total assets	20,166	25,883	29,057	32,522	36,892
Net debt	(7,600)	(3,930)	(6,508)	(9,044)	(13,001)
Capital employed	20,166	25,883	29,057	32,522	36,892
Invested capital	11,014	17,901	18,543	20,073	20,985
BVPS (Rs)	291.5	342.4	391.8	454.5	529.8
Net Debt/Equity (x)	(0.4)	(0.2)	(0.3)	(0.3)	(0.4)
Net Debt/EBITDA (x)	(1.7)	(0.8)	(1.1)	(1.3)	(1.6)
Interest coverage (x)	0.1	0.1	0.1	0.1	0.0
RoCE (%)	21.3	20.2	19.2	21.3	22.3

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	33.5	30.8	29.1	22.9	19.0
P/CE(x)	26.8	24.8	23.5	19.2	16.4
P/B (x)	6.0	5.1	4.5	3.9	3.3
EV/Sales (x)	2.9	2.6	2.1	1.8	1.6
EV/EBITDA (x)	23.0	21.2	17.7	14.4	12.1
EV/EBIT(x)	28.2	25.6	20.9	16.6	13.7
EV/IC (x)	9.3	5.9	5.6	5.0	4.6
FCFF yield (%)	0.3	(1.2)	2.6	3.7	4.6
FCFE yield (%)	0.4	(1.3)	2.2	3.4	4.3
Dividend yield (%)	0.3	0.6	0.6	0.8	1.0
DuPont-RoE split					
Net profit margin (%)	9.2	8.9	7.8	8.7	9.3
Total asset turnover (x)	1.9	1.7	1.8	1.8	1.8
Assets/Equity (x)	1.1	1.2	1.2	1.2	1.1
RoE (%)	18.7	18.0	16.5	18.1	18.8
DuPont-RoIC					
NOPLAT margin (%)	8.9	8.8	8.3	8.8	9.1
IC turnover (x)	3.9	2.8	2.7	2.9	3.0
RoIC (%)	34.9	24.4	22.0	25.2	27.7
Operating metrics					
Core NWC days	15.2	81.1	77.1	82.3	82.2
Total NWC days	15.2	81.1	77.1	82.3	82.2
Fixed asset turnover	3.2	3.4	4.0	4.5	5.0
Opex-to-revenue (%)	87.6	87.5	87.9	87.3	87.1

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 07/25/2024 03:47 PM


Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
01-Jul-24	1,836	1,800	Add	Dipeshkumar Mehta
09-Jun-24	1,495	1,700	Add	Dipeshkumar Mehta
03-Jun-24	1,461	1,700	Add	Dipeshkumar Mehta
27-May-24	1,430	1,700	Add	Dipeshkumar Mehta
06-May-24	1,535	1,700	Add	Dipeshkumar Mehta
31-Mar-24	1,602	1,750	Add	Dipeshkumar Mehta
01-Mar-24	1,594	1,750	Add	Dipeshkumar Mehta
24-Jan-24	1,565	1,750	Add	Dipeshkumar Mehta
31-Dec-23	1,599	1,750	Add	Dipeshkumar Mehta
30-Nov-23	1,550	1,720	Add	Dipeshkumar Mehta
28-Oct-23	1,579	1,720	Hold	Dipeshkumar Mehta
02-Oct-23	1,591	1,720	Hold	Dipeshkumar Mehta
12-Sep-23	1,569	1,720	Hold	Dipeshkumar Mehta
28-Jul-23	1,501	1,670	Hold	Dipeshkumar Mehta
17-Jul-23	1,488	1,670	Hold	Dipeshkumar Mehta
02-Jul-23	1,593	1,670	Hold	Dipeshkumar Mehta
20-May-23	1,398	1,500	Hold	Dipeshkumar Mehta
01-Apr-23	1,366	1,380	Hold	Dipeshkumar Mehta
24-Jan-23	1,230	1,340	Hold	Dipeshkumar Mehta
02-Jan-23	1,216	1,500	Hold	Dipeshkumar Mehta
22-Oct-22	1,308	1,500	Hold	Dipeshkumar Mehta
04-Oct-22	1,392	1,500	Hold	Dipeshkumar Mehta
30-Jul-22	1,401	1,500	Hold	Dipeshkumar Mehta
23-Jun-22	1,194	1,500	Buy	Dipeshkumar Mehta
20-May-22	1,286	1,630	Buy	Dipeshkumar Mehta
01-Apr-22	1,566	2,150	Buy	Dipeshkumar Mehta
22-Feb-22	1,500	2,150	Buy	Dipeshkumar Mehta
28-Jan-22	1,609	2,330	Buy	Dipeshkumar Mehta
27-Aug-21	1,889	2,420	Buy	Dipeshkumar Mehta
29-Jul-21	2,075	2,420	Buy	Dipeshkumar Mehta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 23, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 23, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 23, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.